UNDERSTANDING THE PEPTIDE
Supports Collagen & Elastin Production
GHK-Cu is studied for its role in stimulating collagen types I, III, and IV and elastin synthesis in skin tissue.
Helps Remodel Skin Tissue
Research suggests it can help regulate the balance between building new tissue and clearing damaged tissue.
Antioxidant and Calming Support
Preclinical research points to antioxidant and anti-inflammatory activity.
Supports the Skin’s Repair Response
GHK-Cu is studied for its role in attracting the body’s own repair processes to the treated area.
WHAT RESEARCH IS EXPLORING
Firmness & Elasticity
May help support the look of firmer, more elastic skin.
Smoother-Looking Texture
Some research suggests support for a smoother-looking skin texture.
Natural Renewal Support
May help support the skin’s natural renewal process.
Calmer-Looking Skin
Preclinical findings suggest potential support for calmer-looking skin.
Research Context
A 2024 randomized controlled trial of topical 0.1% GHK-Cu over 12 weeks reported improvements in wrinkle appearance and elasticity versus placebo. Individual results vary, and this finding is not a guarantee of results.
When to check with a clinician
Speak with a clinician before use if you have a copper sensitivity, Wilson disease, liver disease, or another copper-metabolism condition. Pregnant or breastfeeding individuals should consult a doctor first. Compounded and prescription formats require clinician review.
Important treatment information
Prescription treatment requires a consultation and clinical review. If prescribed, medication is dispensed by a licensed pharmacy and availability may vary by location. Compounded preparations are not evaluated by the FDA for safety, effectiveness, or quality. Individual results, eligibility, treatment costs, and shipping timing vary. Consult a licensed clinician to determine whether treatment may be appropriate for you.
The assessment made available on the IRON website does not create a doctor-patient relationship between the individual completing the assessment and IRON. OpenLoop Health, a network of US-licensed doctors that adhere to rigorous medical protocols designed for patient safety, has established exclusionary criteria to determine if an individual does not qualify for GLP-1s. The answers an individual provides to the IRON assessment consequently determine if the individual is screened out of eligibility for GLP-1 medication, and an OpenLoop Health clinician will meet with an individual after checkout to determine if they qualify for a prescription. OpenLoop Health clinicians retain the decision to prescribe compounded GLP-1s to patients. All claims and benefits on this website refer to self-reported data from GLP-1 customers on a treatment plan that includes compounded GLP-1 medications and consultations with medical professionals. Customers reported their weight on their initial medical intake questionnaire every 3-4 weeks thereafter. Results from compounded medications found on the IRON platform may vary and be affected by an individual’s adherence to the program and their clinician’s recommendations. Compounded GLP-1s are produced in FDA-regulated facilities. Although these facilities are highly regulated, the medications are not FDA-approved or evaluated for safety, efficacy, or quality. The decision to use compounded drugs is guided by the licensed provider’s medical judgment, which is informed by a telehealth consultation and medical history. We encourage all prospective users of compounded medications to speak with their provider about the specific risks and benefits that may come with the use of compounded medication. IRON does not produce compounded medications, and individuals may receive medication that looks different than what is portrayed on the website.
© 2026 IRON Rx. All rights reserved
